Vés al contingut

A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD)

Obert
  • Codi protocol: BGB-290-202
  • Codi EudraCT: 2018-002587-28
  • Servei: Sense classificar
  • Investigador/a principal:  Valderrama Rodríguez, Angelica
  • Fase: Fase II